227 results on '"Garzoni C"'
Search Results
2. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients
- Author
-
Cusini, A., Béguelin, C., Stampf, S., Boggian, K., Garzoni, C., Koller, M., Manuel, O., Meylan, P., Mueller, N.J., Hirsch, H.H., Weisser, M., Berger, C., and van Delden, C.
- Published
- 2018
- Full Text
- View/download PDF
3. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
- Author
-
Reinwald, M., Silva, J.T., Mueller, N.J., Fortún, J., Garzoni, C., de Fijter, J.W., Fernández-Ruiz, M., Grossi, P., and Aguado, J.M.
- Published
- 2018
- Full Text
- View/download PDF
4. Surgical site infections after simultaneous pancreas kidney and pancreas transplantation in the Swiss Transplant Cohort Study
- Author
-
Schreiber, P.W., primary, Laager, M., additional, Boggian, K., additional, Neofytos, D., additional, van Delden, C., additional, Egli, A., additional, Dickenmann, M., additional, Hirzel, C., additional, Manuel, O., additional, Koller, M., additional, Rossi, S., additional, Schmied, B., additional, Gürke, L., additional, Matter, M., additional, Berney, T., additional, de Rougemont, O., additional, Kuster, S.P., additional, Stampf, S., additional, Mueller, N.J., additional, Amico, P., additional, Aubert, J-D., additional, Banz, V., additional, Beckmann, S., additional, Beldi, G., additional, Berger, C., additional, Berishvili, E., additional, Berzigotti, A., additional, Binet, I., additional, Bochud, P-Y., additional, Branca, S., additional, Bucher, H., additional, Catana, E., additional, Cairoli, A., additional, Chalandon, Y., additional, De Geest, S., additional, De Rougemont, O., additional, De Seigneux, S., additional, Dreifuss, J.L., additional, Duchosal, M., additional, Fehr, T., additional, Ferrari-Lacraz, S., additional, Garzoni, C., additional, Golshayan, D., additional, Goossens, N., additional, Halter, F.H.J., additional, Heim, D., additional, Hess, C., additional, Hillinger, S., additional, Hirsch, H.H., additional, Hirt, P., additional, Hofbauer, G., additional, Huynh-Do, U., additional, Immer, F., additional, Laesser, B., additional, Lamoth, F., additional, Lehmann, R., additional, Leichtle, A., additional, Marti, H.P., additional, Martinelli, M., additional, McLin, V., additional, Mellac, K., additional, Merçay, A., additional, Mettler, K., additional, Müller, A., additional, Müller-Arndt, U., additional, Müllhaupt, B., additional, Nägeli, M., additional, Oldani, G., additional, Pascual, M., additional, Passweg, J., additional, Pazeller, R., additional, Posfay-Barbe, K., additional, Rick, J., additional, Rosselet, A., additional, Rothlin, S., additional, Ruschitzka, F., additional, Schachtner, T., additional, Schanz, U., additional, Schaub, S., additional, Scherrer, A., additional, Schnyder, A., additional, Schuurmans, M., additional, Schwab, S., additional, Sengstag, T., additional, Simonetta, F., additional, Steiger, J., additional, Stirnimann, G., additional, Stürzinger, U., additional, Van Delden, C., additional, Venetz, J-P., additional, Villard, J., additional, Vionnet, J., additional, Wick, M., additional, Wilhelm, M., additional, and Yerly, P., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor–derived infections
- Author
-
Len, O., Garzoni, C., Lumbreras, C., Molina, I., Meije, Y., Pahissa, A., and Grossi, P.
- Published
- 2014
- Full Text
- View/download PDF
6. Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant Recipients
- Author
-
Manuel, O., Kralidis, G., Mueller, N.J., Hirsch, H.H., Garzoni, C., van Delden, C., Berger, C., Boggian, K., Cusini, A., Koller, M.T., Weisser, M., Pascual, M., and Meylan, P.R.
- Published
- 2013
- Full Text
- View/download PDF
7. Methicillin-Resistant, Vancomycin-Intermediate and Vancomycin-Resistant Staphylococcus aureus Infections in Solid Organ Transplantation
- Author
-
Garzoni, C. and Vergidis, P.
- Published
- 2013
- Full Text
- View/download PDF
8. KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients
- Author
-
Gonzalez, A, Schmitter, K, Hirsch, H H, Garzoni, C, van Delden, C, Boggian, K, Mueller, N J, Berger, C, Villard, J, Manuel, O, Meylan, P, Stern, M, and Hess, C
- Published
- 2014
- Full Text
- View/download PDF
9. Outbreak investigation for toxigenic Corynebacterium diphtheriae wound infections in refugees from Northeast Africa and Syria in Switzerland and Germany by whole genome sequencing
- Author
-
Meinel, D.M., Kuehl, R., Zbinden, R., Boskova, V., Garzoni, C., Fadini, D., Dolina, M., Blümel, B., Weibel, T., Tschudin-Sutter, S., Widmer, A.F., Bielicki, J.A., Dierig, A., Heininger, U., Konrad, R., Berger, A., Hinic, V., Goldenberger, D., Blaich, A., Stadler, T., Battegay, M., Sing, A., and Egli, A.
- Published
- 2016
- Full Text
- View/download PDF
10. Multiply Resistant Gram-Positive Bacteria Methicillin-Resistant, Vancomycin-Intermediate and Vancomycin-Resistant Staphylococcus aureus (MRSA, VISA, VRSA) in Solid Organ Transplant Recipients
- Author
-
Garzoni, C.
- Published
- 2009
- Full Text
- View/download PDF
11. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- Author
-
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., Bianchi, S., Tortorici, M. A., Bowen, J., Culap, K., Jaconi, S., Cameroni, E., Snell, G., Pizzuto, M. S., Pellanda, A. F., Garzoni, C., Riva, A., Baker, S., Dougan, G., Hess, C., Kingston, N., Lehner, P. J., Lyons, P. A., Matheson, N. J., Owehand, W. H., Saunders, C., Summers, C., Thaventhiran, J. E. D., Toshner, M., Weekes, M. P., Bucke, A., Calder, J., Canna, L., Domingo, J., Elmer, A., Fuller, S., Harris, J., Hewitt, S., Kennet, J., Jose, S., Kourampa, J., Meadows, A., O'Brien, C., Price, J., Publico, C., Rastall, R., Ribeiro, C., Rowlands, J., Ruffolo, V., Tordesillas, H., Bullman, B., Dunmore, B. J., Fawke, S., Graf, S., Hodgson, J., Huang, C., Hunter, K., Jones, E., Legchenko, E., Matara, C., Martin, J., Mescia, F., O'Donnell, C., Pointon, L., Pond, N., Shih, J., Sutcliffe, R., Tilly, T., Treacy, C., Tong, Z., Wood, J., Wylot, M., Bergamaschi, L., Betancourt, A., Bower, G., Cossetti, C., De Sa, A., Epping, M., Grenfell, R., Hinch, A., Huhn, O., Jackson, S., Jarvis, I., Lewis, D., Marsden, J., Nice, F., Okecha, G., Omarjee, O., Perera, M., Richoz, N., Romashova, V., Yarkoni, N. S., Sharma, R., Stefanucci, L., Stephens, J., Strezlecki, M., Turner, L., De Bie, E. M. D. D., Bunclark, K., Josipovic, M., Mackay, M., Rossi, S., Selvan, M., Spencer, S., Yong, C., Ansaripour, A., Michael, A., Mwaura, L., Patterson, C., Polwarth, G., Polgarova, P., di Stefano, G., Fahey, C., Michel, R., Bong, S. -H., Coudert, J. D., Holmes, E., Allison, J., Butcher, H., Caputo, D., Clapham-Riley, D., Dewhurst, E., Furlong, A., Graves, B., Gray, J., Ivers, T., Kasanicki, M., Le Gresley, E., Linger, R., Meloy, S., Muldoon, F., Ovington, N., Papadia, S., Phelan, I., Stark, H., Stirrups, K. E., Townsend, P., Walker, N., Webster, J., Mccoy, L. E., Smith, K. G. C., Bradley, J. R., Temperton, N., Ceron-Gutierrez, L., Barcenas-Morales, G., Robson, S. C., Loman, N. J., Connor, T. R., Golubchik, T., Martinez Nunez, R. T., Ludden, C., Corden, S., Johnston, I., Bonsall, D., Smith, C. P., Awan, A. R., Bucca, G., Torok, M. E., Saeed, K., Prieto, J. A., Jackson, D. K., Hamilton, W. L., Snell, L. B., Moore, C., Harrison, E. M., Goncalves, S., Fairley, D. J., Loose, M. W., Watkins, J., Livett, R., Moses, S., Amato, R., Nicholls, S., Bull, M., Smith, D. L., Barrett, J., Aanensen, D. M., Curran, M. D., Parmar, S., Aggarwal, D., Shepherd, J. G., Parker, M. D., Glaysher, S., Bashton, M., Underwood, A. P., Pacchiarini, N., Loveson, K. F., Carabelli, A. M., Templeton, K. E., Langford, C. F., Sillitoe, J., de Silva, T. I., Wang, D., Kwiatkowski, D., Rambaut, A., O'Grady, J., Cottrell, S., Holden, M. T. G., Thomson, E. C., Osman, H., Andersson, M., Chauhan, A. J., Hassan-Ibrahim, M. O., Lawniczak, M., Alderton, A., Chand, M., Constantinidou, C., Unnikrishnan, M., Darby, A. C., Hiscox, J. A., Paterson, S., Martincorena, I., Robertson, D. L., Volz, E. M., Page, A. J., Pybus, O. G., Bassett, A. R., Ariani, C. V., Spencer Chapman, M. H., K. K., Li, Shah, R. N., Jesudason, N. G., Taha, Y., Mchugh, M. P., Dewar, R., Jahun, A. S., Mcmurray, C., Pandey, S., Mckenna, J. P., Nelson, A., Young, G. R., Mccann, C. M., Elliott, S., Lowe, H., Temperton, B., Roy, S., Price, A., Rey, S., Wyles, M., Rooke, S., Shaaban, S., de Cesare, M., Letchford, L., Silveira, S., Pelosi, E., Wilson-Davies, E., Hosmillo, M., O'Toole, A., Hesketh, A. R., Stark, R., du Plessis, L., Ruis, C., Adams, H., Bourgeois, Y., Michell, S. L., Gramatopoulos, D., Edgeworth, J., Breuer, J., Todd, J. A., Fraser, C., Buck, D., John, M., Kay, G. L., Palmer, S., Peacock, S. J., Heyburn, D., Weldon, D., Robinson, E., Mcnally, A., Muir, P., Vipond, I. B., Boyes, J., Sivaprakasam, V., Salluja, T., Dervisevic, S., Meader, E. J., Park, N. R., Oliver, K., Jeffries, A. R., Ott, S., da Silva Filipe, A., Simpson, D. A., Williams, C., Masoli, J. A. H., Knight, B. A., Jones, C. R., Koshy, C., Ash, A., Casey, A., Bosworth, A., Ratcliffe, L., Xu-McCrae, L., Pymont, H. M., Hutchings, S., Berry, L., Jones, K., Halstead, F., Davis, T., Holmes, C., Iturriza-Gomara, M., Lucaci, A. O., Randell, P. A., Cox, A., Madona, P., Harris, K. A., Brown, J. R., Mahungu, T. W., Irish-Tavares, D., Haque, T., Hart, J., Witele, E., Fenton, M. L., Liggett, S., Graham, C., Swindells, E., Collins, J., Eltringham, G., Campbell, S., Mcclure, P. C., Clark, G., Sloan, T. J., Jones, C., Lynch, J., Warne, B., Leonard, S., Durham, J., Williams, T., Haldenby, S. T., Storey, N., Alikhan, N. -F., Holmes, N., Carlile, M., Perry, M., Craine, N., Lyons, R. A., Beckett, A. H., Goudarzi, S., Fearn, C., Cook, K., Dent, H., Paul, H., Davies, R., Blane, B., Girgis, S. T., Beale, M. A., Bellis, K. L., Dorman, M. J., Drury, E., Kane, L., Kay, S., Mcguigan, S., Nelson, R., Prestwood, L., Rajatileka, S., Batra, R., Williams, R. J., Kristiansen, M., Green, A., Justice, A., Mahanama, A. I. K., Samaraweera, B., Hadjirin, N. F., Quick, J., Poplawski, R., Kermack, L. M., Reynolds, N., Hall, G., Chaudhry, Y., Pinckert, M. L., Georgana, I., Moll, R. J., Thornton, A., Myers, R., Stockton, J., Williams, C. A., Yew, W. C., Trotter, A. J., Trebes, A., MacIntyre-Cockett, G., Birchley, A., Adams, A., Plimmer, A., Gatica-Wilcox, B., Mckerr, C., Hilvers, E., Jones, H., Asad, H., Coombes, J., Evans, J. M., Fina, L., Gilbert, L., Graham, L., Cronin, M., Kumziene-Summerhayes, S., Taylor, S., Jones, S., Groves, D. C., Zhang, P., Gallis, M., Louka, S. F., Starinskij, I., Jackson, C., Gourtovaia, M., Tonkin-Hill, G., Lewis, K., Tovar-Corona, J. M., James, K., Baxter, L., Alam, M. T., Orton, R. J., Hughes, J., Vattipally, S., Ragonnet-Cronin, M., Nascimento, F. F., Jorgensen, D., Boyd, O., Geidelberg, L., Zarebski, A. E., Raghwani, J., Kraemer, M. U. G., Southgate, J., Lindsey, B. B., Freeman, T. M., Keatley, J. -P., Singer, J. B., de Oliveira Martins, L., Yeats, C. A., Abudahab, K., Taylor, B. E. W., Menegazzo, M., Danesh, J., Hogsden, W., Eldirdiri, S., Kenyon, A., Mason, J., Robinson, T. I., Holmes, A., Hartley, J. A., Curran, T., Mather, A. E., Shankar, G., Jones, R., Howe, R., Morgan, S., Wastenge, E., Chapman, M. R., Mookerjee, S., Stanley, R., Smith, W., Peto, T., Eyre, D., Crook, D., Vernet, G., Kitchen, C., Gulliver, H., Merrick, I., Guest, M., Munn, R., Bradley, D. T., Wyatt, T., Beaver, C., Foulser, L., Churcher, C. M., Brooks, E., Smith, K. S., Galai, K., Mcmanus, G. M., Bolt, F., Coll, F., Meadows, L., Attwood, S. W., Davies, A., De Lacy, E., Downing, F., Edwards, S., Scarlett, G. P., Jeremiah, S., Smith, N., Leek, D., Sridhar, S., Forrest, S., Cormie, C., Gill, H. K., Dias, J., Higginson, E. E., Maes, M., Young, J., Wantoch, M., Jamrozy, D., Lo, S., Patel, M., Hill, V., Bewshea, C. M., Ellard, S., Auckland, C., Harrison, I., Bishop, C., Chalker, V., Richter, A., Beggs, A., Best, A., Percival, B., Mirza, J., Megram, O., Mayhew, M., Crawford, L., Ashcroft, F., Moles-Garcia, E., Cumley, N., Hopes, R., Asamaphan, P., Niebel, M. O., Gunson, R. N., Bradley, A., Maclean, A., Mollett, G., Blacow, R., Bird, P., Helmer, T., Fallon, K., Tang, J., Hale, A. D., Macfarlane-Smith, L. R., Harper, K. L., Carden, H., Machin, N. W., Jackson, K. A., Ahmad, S. S. Y., George, R. P., Turtle, L., O'Toole, E., Watts, J., Breen, C., Cowell, A., Alcolea-Medina, A., Charalampous, T., Patel, A., Levett, L. J., Heaney, J., Rowan, A., Taylor, G. P., Shah, D., Atkinson, L., Lee, J. C. D., Westhorpe, A. P., Jannoo, R., Lowe, H. L., Karamani, A., Ensell, L., Chatterton, W., Pusok, M., Dadrah, A., Symmonds, A., Sluga, G., Molnar, Z., Baker, P., Bonner, S., Essex, S., Barton, E., Padgett, D., Scott, G., Greenaway, J., Payne, B. A. I., Burton-Fanning, S., Waugh, S., Raviprakash, V., Sheriff, N., Blakey, V., Williams, L. -A., Moore, J., Stonehouse, S., Smith, L., Davidson, R. K., Bedford, L., Coupland, L., Wright, V., Chappell, J. G., Tsoleridis, T., Ball, J., Khakh, M., Fleming, V. M., Lister, M. M., Howson-Wells, H. C., Boswell, T., Joseph, A., Willingham, I., Duckworth, N., Walsh, S., Wise, E., Moore, N., Mori, M., Cortes, N., Kidd, S., Williams, R., Gifford, L., Bicknell, K., Wyllie, S., Lloyd, A., Impey, R., Malone, C. S., Cogger, B. J., Levene, N., Monaghan, L., Keeley, A. J., Partridge, D. G., Raza, M., Evans, C., Johnson, K., Betteridge, E., Farr, B. W., Goodwin, S., Quail, M. A., Scott, C., Shirley, L., Thurston, S. A. J., Rajan, D., Bronner, I. F., Aigrain, L., Redshaw, N. M., Lensing, S. V., Mccarthy, S., Makunin, A., Balcazar, C. E., Gallagher, M. D., Williamson, K. A., Stanton, T. D., Michelsen, M. L., Warwick-Dugdale, J., Manley, R., Farbos, A., Harrison, J. W., Sambles, C. M., Studholme, D. J., Lackenby, A., Mbisa, T., Platt, S., Miah, S., Bibby, D., Manso, C., Hubb, J., Dabrera, G., Ramsay, M., Bradshaw, D., Schaefer, U., Groves, N., Gallagher, E., Lee, D., Williams, D., Ellaby, N., Hartman, H., Manesis, N., Patel, V., Ledesma, J., Twohig, K. A., Allara, E., Pearson, C., Cheng, J. K. J., Bridgewater, H. E., Frost, L. R., Taylor-Joyce, G., Brown, P. E., Tong, L., Broos, A., Mair, D., Nichols, J., Carmichael, S. N., Smollett, K. L., Nomikou, K., Aranday-Cortes, E., Johnson, N., Nickbakhsh, S., Vamos, E. E., Hughes, M., Rainbow, L., Eccles, R., Nelson, C., Whitehead, M., Gregory, R., Gemmell, M., Wierzbicki, C., Webster, H. J., Fisher, C. L., Signell, A. W., Betancor, G., Wilson, H. D., Nebbia, G., Flaviani, F., Cerda, A. C., Merrill, T. V., Wilson, R. E., Cotic, M., Bayzid, N., Thompson, T., Acheson, E., Rushton, S., O'Brien, S., Baker, D. J., Rudder, S., Aydin, A., Sang, F., Debebe, J., Francois, S., Vasylyeva, T. I., Zamudio, M. E., Gutierrez, B., Marchbank, A., Maksimovic, J., Spellman, K., Mccluggage, K., Morgan, M., Beer, R., Afifi, S., Workman, T., Fuller, W., Bresner, C., Angyal, A., Green, L. R., Parsons, P. J., Tucker, R. M., Brown, R., Whiteley, M., Bonfield, J., Puethe, C., Whitwham, A., Liddle, J., Rowe, W., Siveroni, I., Le-Viet, T., Gaskin, A., Johnson, R., Abnizova, I., Ali, M., Allen, L., Anderson, R., Ariani, C., Austin-Guest, S., Bala, S., Bassett, A., Battleday, K., Beal, J., Beale, M., Bellany, S., Bellerby, T., Bellis, K., Berger, D., Berriman, M., Bevan, P., Binley, S., Bishop, J., Blackburn, K., Boughton, N., Bowker, S., Brendler-Spaeth, T., Bronner, I., Brooklyn, T., Buddenborg, S. K., Bush, R., Caetano, C., Cagan, A., Carter, N., Cartwright, J., Monteiro, T. C., Chapman, L., Chillingworth, T. -J., Clapham, P., Clark, R., Clarke, A., Clarke, C., Cole, D., Cook, E., Coppola, M., Cornell, L., Cornwell, C., Corton, C., Crackett, A., Cranage, A., Craven, H., Craw, S., Crawford, M., Cutts, T., Dabrowska, M., Davies, M., Dawson, J., Day, C., Densem, A., Dibling, T., Dockree, C., Dodd, D., Dogga, S., Dougherty, M., Dove, A., Drummond, L., Dudek, M., Durrant, L., Easthope, E., Eckert, S., Ellis, P., Farr, B., Fenton, M., Ferrero, M., Flack, N., Fordham, H., Forsythe, G., Francis, M., Fraser, A., Freeman, A., Galvin, A., Garcia-Casado, M., Gedny, A., Girgis, S., Glover, J., Gould, O., Gray, A., Gray, E., Griffiths, C., Gu, Y., Guerin, F., Hamilton, W., Hanks, H., Harrison, E., Harrott, A., Harry, E., Harvison, J., Heath, P., Hernandez-Koutoucheva, A., Hobbs, R., Holland, D., Holmes, S., Hornett, G., Hough, N., Huckle, L., Hughes-Hallet, L., Hunter, A., Inglis, S., Iqbal, S., Jackson, A., Jackson, D., Verdejo, C. J., Jones, M., Kallepally, K., Kay, K., Keatley, J., Keith, A., King, A., Kitchin, L., Kleanthous, M., Klimekova, M., Korlevic, P., Krasheninnkova, K., Lane, G., Langford, C., Laverack, A., Law, K., Lensing, S., Lewis-Wade, A., Lin, Q., Lindsay, S., Linsdell, S., Long, R., Lovell, J., Mack, J., Maddison, M., Mamun, I., Mansfield, J., Marriott, N., Martin, M., Mayho, M., Mcclintock, J., Mchugh, S., Mcminn, L., Meadows, C., Mobley, E., Moll, R., Morra, M., Morrow, L., Murie, K., Nash, S., Nathwani, C., Naydenova, P., Neaverson, A., Nerou, E., Nicholson, J., Nimz, T., Noell, G. G., O'Meara, S., Ohan, V., Olney, C., Ormond, D., Oszlanczi, A., Pang, Y. F., Pardubska, B., Park, N., Parmar, A., Patel, G., Payne, M., Peacock, S., Petersen, A., Plowman, D., Preston, T., Quail, M., Rance, R., Rawlings, S., Redshaw, N., Reynolds, J., Reynolds, M., Rice, S., Richardson, M., Roberts, C., Robinson, K., Robinson, M., Robinson, D., Rogers, H., Rojo, E. M., Roopra, D., Rose, M., Rudd, L., Sadri, R., Salmon, N., Saul, D., Schwach, F., Seekings, P., Simms, A., Sinnott, M., Sivadasan, S., Siwek, B., Sizer, D., Skeldon, K., Skelton, J., Slater-Tunstill, J., Sloper, L., Smerdon, N., Smith, C., Smith, J., Smith, K., Smith, M., Smith, S., Smith, T., Sneade, L., Soria, C. D., Sousa, C., Souster, E., Sparkes, A., Spencer-Chapman, M., Squares, J., Steed, C., Stickland, T., Still, I., Stratton, M., Strickland, M., Swann, A., Swiatkowska, A., Sycamore, N., Swift, E., Symons, E., Szluha, S., Taluy, E., Tao, N., Taylor, K., Thompson, S., Thompson, M., Thomson, M., Thomson, N., Thurston, S., Toombs, D., Topping, B., Tovar-Corona, J., Ungureanu, D., Uphill, J., Urbanova, J., Van, P. J., Vancollie, V., Voak, P., Walker, D., Walker, M., Waller, M., Ward, G., Weatherhogg, C., Webb, N., Wells, A., Wells, E., Westwood, L., Whipp, T., Whiteley, T., Whitton, G., Widaa, S., Williams, M., Wilson, M., Wright, S., Harvey, W., Virgin, H. W., Lanzavecchia, A., Piccoli, L., Doffinger, R., Wills, M., Veesler, D., Corti, D., and Gupta, R. K.
- Subjects
0301 basic medicine ,Male ,Models, Molecular ,Passive ,Antibodies, Viral ,Neutralization ,0302 clinical medicine ,Models ,Monoclonal ,80 and over ,Viral ,Neutralizing antibody ,Neutralizing ,Aged, 80 and over ,Vaccines ,Vaccines, Synthetic ,Multidisciplinary ,biology ,Antibodies, Monoclonal ,C500 ,Middle Aged ,C700 ,Spike Glycoprotein ,Vaccination ,Spike Glycoprotein, Coronavirus ,Female ,Angiotensin-Converting Enzyme 2 ,Antibody ,Aged ,Antibodies, Neutralizing ,COVID-19 ,COVID-19 Vaccines ,HEK293 Cells ,Humans ,Immune Evasion ,Immunization, Passive ,Mutation ,Neutralization Tests ,SARS-CoV-2 ,medicine.drug_class ,B100 ,Monoclonal antibody ,Antibodies ,Virus ,03 medical and health sciences ,Immune system ,medicine ,COVID-19 Serotherapy ,QR355 ,Synthetic ,Molecular ,Virology ,Coronavirus ,030104 developmental biology ,Immunization ,biology.protein ,030217 neurology & neurosurgery - Abstract
Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant1, which has now been reported in 94 countries. It is unclear whether the response of the virus to vaccines against SARS-CoV-2 on the basis of the prototypic strain will be affected by the mutations found in B.1.1.7. Here we assess the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b22. We measured neutralizing antibody responses after the first and second immunizations using pseudoviruses that expressed the wild-type spike protein or a mutated spike protein that contained the eight amino acid changes found in the B.1.1.7 variant. The sera from individuals who received the vaccine exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against the B.1.1.7 variant. This reduction was also evident in sera from some patients who had recovered from COVID-19. Decreased neutralization of the B.1.1.7 variant was also observed for monoclonal antibodies that target the N-terminal domain (9 out of 10) and the receptor-binding motif (5 out of 31), but not for monoclonal antibodies that recognize the receptor-binding domain that bind outside the receptor-binding motif. Introduction of the mutation that encodes the E484K substitution in the B.1.1.7 background to reflect a newly emerged variant of concern (VOC 202102/02) led to a more-substantial loss of neutralizing activity by vaccine-elicited antibodies and monoclonal antibodies (19 out of 31) compared with the loss of neutralizing activity conferred by the mutations in B.1.1.7 alone. The emergence of the E484K substitution in a B.1.1.7 background represents a threat to the efficacy of the BNT162b2 vaccine.
- Published
- 2021
12. Broad betacoronavirus neutralization by a stem helix–specific human antibody
- Author
-
Pinto, D, Sauer, MM, Czudnochowski, N, Low, JS, Alejandra Tortorici, M, Housley, MP, Noack, J, Walls, AC, Bowen, JE, Guarino, B, Rosen, LE, di Iulio, J, Jerak, J, Kaiser, H, Islam, S, Jaconi, S, Sprugasci, N, Culap, K, Abdelnabi, R, Foo, C, Coelmont, L, Bartha, I, Bianchi, S, Silacci-Fregni, C, Bassi, J, Marzi, R, Vetti, E, Cassotta, A, Ceschi, A, Ferrari, P, Cippà, PE, Giannini, O, Ceruti, S, Garzoni, C, Riva, A, Benigni, F, Cameroni, E, Piccoli, L, Pizzuto, MS, Smithey, M, Hong, D, Telenti, A, Lempp, FA, Neyts, J, Havenar-Daughton, C, Lanzavecchia, A, Sallusto, F, Snell, G, Virgin, HW, Beltramello, M, Corti, D, Veesler, D, Pinto, D, Sauer, MM, Czudnochowski, N, Low, JS, Alejandra Tortorici, M, Housley, MP, Noack, J, Walls, AC, Bowen, JE, Guarino, B, Rosen, LE, di Iulio, J, Jerak, J, Kaiser, H, Islam, S, Jaconi, S, Sprugasci, N, Culap, K, Abdelnabi, R, Foo, C, Coelmont, L, Bartha, I, Bianchi, S, Silacci-Fregni, C, Bassi, J, Marzi, R, Vetti, E, Cassotta, A, Ceschi, A, Ferrari, P, Cippà, PE, Giannini, O, Ceruti, S, Garzoni, C, Riva, A, Benigni, F, Cameroni, E, Piccoli, L, Pizzuto, MS, Smithey, M, Hong, D, Telenti, A, Lempp, FA, Neyts, J, Havenar-Daughton, C, Lanzavecchia, A, Sallusto, F, Snell, G, Virgin, HW, Beltramello, M, Corti, D, and Veesler, D
- Abstract
The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus countermeasures. We describe five monoclonal antibodies (mAbs) cross-reacting with the stem helix of multiple betacoronavirus spike glycoproteins isolated from COVID-19 convalescent individuals. Using structural and functional studies, we show that the mAb with the greatest breadth (S2P6) neutralizes pseudotyped viruses from three different subgenera through the inhibition of membrane fusion, and we delineate the molecular basis for its cross-reactivity. S2P6 reduces viral burden in hamsters challenged with SARS-CoV-2 through viral neutralization and Fc-mediated effector functions. Stem helix antibodies are rare, oftentimes of narrow specificity, and can acquire neutralization breadth through somatic mutations. These data provide a framework for structure-guided design of pan-betacoronavirus vaccines eliciting broad protection.
- Published
- 2021
13. Clonal analysis of immunodominance and crossreactivity of the CD4 T cell response to SARS-CoV-2
- Author
-
Low, JS, Vaqueirinho, D, Mele, F, Foglierini, M, Jerak, J, Perotti, M, Jarrossay, D, Jovic, S, Perez, L, Cacciatore, R, Terrot, T, Pellanda, AF, Biggiogero, M, Garzoni, C, Ferrari, P, Ceschi, A, Lanzavecchia, A, Sallusto, F, Cassotta, A, Low, JS, Vaqueirinho, D, Mele, F, Foglierini, M, Jerak, J, Perotti, M, Jarrossay, D, Jovic, S, Perez, L, Cacciatore, R, Terrot, T, Pellanda, AF, Biggiogero, M, Garzoni, C, Ferrari, P, Ceschi, A, Lanzavecchia, A, Sallusto, F, and Cassotta, A
- Abstract
The identification of CD4+ T cell epitopes is instrumental for the design of subunit vaccines for broad protection against coronaviruses. Here, we demonstrate in COVID-19-recovered individuals a robust CD4+ T cell response to naturally processed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and nucleoprotein (N), including effector, helper, and memory T cells. By characterizing 2943 S-reactive T cell clones from 34 individuals, we found that the receptor-binding domain (RBD) is highly immunogenic and that 33% of RBD-reactive clones and 94% of individuals recognized a conserved immunodominant S346-S365 region comprising nested human leukocyte antigen DR (HLA-DR)- and HLA-DP-restricted epitopes. Using pre- and post- COVID-19 samples and S proteins from endemic coronaviruses, we identified cross-reactive T cells targeting multiple S protein sites. The immunodominant and cross-reactive epitopes identified can inform vaccination strategies to counteract emerging SARS-CoV-2 variants.
- Published
- 2021
14. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland
- Author
-
Piccoli, L, Ferrari, P, Piumatti, G, Jovic, S, Rodriguez, BF, Mele, F, Giacchetto-Sasselli, I, Terrot, T, Silacci-Fregni, C, Cameroni, E, Jaconi, S, Sprugasci, N, Bartha, I, Corti, D, Uguccioni, M, Lanzavecchia, A, Garzoni, C, Giannini, O, Bernasconi, E, Elzi, L, Albanese, E, Sallusto, F, Ceschi, A, Piccoli, L, Ferrari, P, Piumatti, G, Jovic, S, Rodriguez, BF, Mele, F, Giacchetto-Sasselli, I, Terrot, T, Silacci-Fregni, C, Cameroni, E, Jaconi, S, Sprugasci, N, Bartha, I, Corti, D, Uguccioni, M, Lanzavecchia, A, Garzoni, C, Giannini, O, Bernasconi, E, Elzi, L, Albanese, E, Sallusto, F, and Ceschi, A
- Abstract
Background: Hospital healthcare workers (HCW), in particular those involved in the clinical care of COVID-19 cases, are presumably exposed to a higher risk of acquiring the disease than the general population. Methods: Between April 16 and 30, 2020 we conducted a prospective, SARS-CoV-2 seroprevalence study in HCWs in Southern Switzerland. Participants were hospital personnel with varying COVID-19 exposure risk depending on job function and working site. They provided personal information (including age, sex, occupation, and medical history) and self-reported COVID-19 symptoms. Odds ratio (OR) of seropositivity to IgG antibodies was estimated by univariate and multivariate logistic regressions. Findings: Among 4726 participants, IgG antibodies to SARS-CoV-2 were detected in 9.6% of the HCWs. Seropositivity was higher among HCWs working on COVID-19 wards (14.1% (11.9–16.5)) compared to other hospital areas at medium (10.7% (7.6–14.6)) or low risk exposure (7.3% (6.4–8.3)). OR for high vs. medium wards risk exposure was 1.42 (0.91–2.22), P = 0.119, and 1.98 (1.55–2.53), P<0.001 for high vs. low wards risk exposure. The same was for true for doctors and nurses (10.1% (9.0–11.3)) compared to other employees at medium (7.1% (4.8–10.0)) or low risk exposure (6.6% (5.0–8.4)). OR for high vs. medium profession risk exposure was 1.37 (0.89–2.11), P = 0.149, and 1.75 (1.28–2.40), P = 0.001 for high vs. low profession risk exposure. Moreover, seropositivity was higher among HCWs who had household exposure to COVID-19 cases compared to those without (18.7% (15.3–22.5) vs. 7.7% (6.9–8.6), OR 2.80 (2.14–3.67), P<0.001). Interpretation: SARS-CoV-2 antibodies are detectable in up to 10% of HCWs from acute care hospitals in a region with high incidence of COVID-19 in the weeks preceding the study. HCWs with exposure to COVID-19 patients have only a slightly higher absolute risk of seropositivity compared to those without, suggesting that the use of PPE and other measures aiming at r
- Published
- 2021
15. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
- Author
-
Thomson, EC, Rosen, LE, Shepherd, JG, Spreafico, R, da Silva Filipe, A, Wojcechowskyj, JA, Davis, C, Piccoli, L, Pascall, DJ, Dillen, J, Lytras, S, Czudnochowski, N, Shah, R, Meury, M, Jesudason, N, De Marco, A, Li, K, Bassi, J, O'Toole, A, Pinto, D, Colquhoun, RM, Culap, K, Jackson, B, Zatta, F, Rambaut, A, Jaconi, S, Sreenu, VB, Nix, J, Zhang, I, Jarrett, RF, Glass, WG, Beltramello, M, Nomikou, K, Pizzuto, M, Tong, L, Cameroni, E, Croll, TI, Johnson, N, Di Iulio, J, Wickenhagen, A, Ceschi, A, Harbison, AM, Mair, D, Ferrari, P, Smollett, K, Sallusto, F, Carmichael, S, Garzoni, C, Nichols, J, Galli, M, Hughes, J, Riva, A, Ho, A, Schiuma, M, Semple, MG, Openshaw, PJM, Fadda, E, Baillie, JK, Chodera, JD, Rihn, SJ, Lycett, SJ, Virgin, HW, Telenti, A, Corti, D, Robertson, DL, Snell, G, Thomson, EC, Rosen, LE, Shepherd, JG, Spreafico, R, da Silva Filipe, A, Wojcechowskyj, JA, Davis, C, Piccoli, L, Pascall, DJ, Dillen, J, Lytras, S, Czudnochowski, N, Shah, R, Meury, M, Jesudason, N, De Marco, A, Li, K, Bassi, J, O'Toole, A, Pinto, D, Colquhoun, RM, Culap, K, Jackson, B, Zatta, F, Rambaut, A, Jaconi, S, Sreenu, VB, Nix, J, Zhang, I, Jarrett, RF, Glass, WG, Beltramello, M, Nomikou, K, Pizzuto, M, Tong, L, Cameroni, E, Croll, TI, Johnson, N, Di Iulio, J, Wickenhagen, A, Ceschi, A, Harbison, AM, Mair, D, Ferrari, P, Smollett, K, Sallusto, F, Carmichael, S, Garzoni, C, Nichols, J, Galli, M, Hughes, J, Riva, A, Ho, A, Schiuma, M, Semple, MG, Openshaw, PJM, Fadda, E, Baillie, JK, Chodera, JD, Rihn, SJ, Lycett, SJ, Virgin, HW, Telenti, A, Corti, D, Robertson, DL, and Snell, G
- Abstract
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics. Epidemiological, clinical, molecular, and structural characterization of the N439K mutation in the SARS-CoV-2 spike receptor binding motif demonstrates that it results in similar viral fitness compared to wild-type while conferring resistance against some neutralizing monoclonal antibodies and reducing the activity of some polyclonal antibody responses.
- Published
- 2021
16. NK Cell Immunity Pre-Transplant as a Predictor for CMV Post-Transplant.: Abstract# 2167
- Author
-
Keshwani, S., Humar, A., Lisboa, L., Egli, A., Bochud, P., Hirsch, H., Weisser, M., Husain, S., Garzoni, C., van Delden, C., Manuel, O., Meylan, P., Boggian, K., Stern, M., Rick, J., Mueller, N., and Kumar, D.
- Published
- 2014
17. Pre-Transplant T-Cell Subtype Assessment as a Predictive Tool for CMV Viremia After Transplant.: Abstract# 2166
- Author
-
Keshwani, S., Kumar, D., Lisboa, L., Egli, A., Bochud, P., Hirsch, H., Weisser, M., Husain, S., Garzoni, C., van Delden, C., Manuel, O., Meylan, P., Boggian, K., Rick, J., Mueller, N., and Humar, A.
- Published
- 2014
18. Opportunistic Infections After Solid Organ Transplantation (SOT) Are Rare in The Swiss Transplant Cohort Study (STCS).: Abstract# 1339
- Author
-
Mueller, N., Saccilotto, R., Meylan, P., Manuel, O., Garzoni, C., Cusini, A., Hirsch, H., Weisser, M., Khanna, N., Boggian, K., Nadal, D., Berger, C., Koller, M., Stampf, S., and van Delden, C.
- Published
- 2014
19. Impact of enterococcal colonization and infection in solid organ transplantation recipients from the Swiss Transplant Cohort Study
- Author
-
Bucheli, E., Kralidis, G., Boggian, K., Cusini, A., Garzoni, C., Manuel, O., Meylan, P. R.A., Mueller, N. J., Khanna, N., van Delden, C., Berger, C., Koller, M. T., and Weisser, M.
- Published
- 2014
- Full Text
- View/download PDF
20. Candida parapsilosis endocarditis: a comparative review of the literature
- Author
-
Garzoni, C., Nobre, V. A., and Garbino, J.
- Published
- 2007
- Full Text
- View/download PDF
21. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- Author
-
Piccoli, L, Park, YJ, Tortorici, MA, Czudnochowski, N, Walls, AC, Beltramello, M, Silacci-Fregni, C, Pinto, D, Rosen, LE, Bowen, JE, Acton, OJ, Jaconi, S, Guarino, B, Minola, A, Zatta, F, Sprugasci, N, Bassi, J, Peter, A, De Marco, A, Nix, JC, Mele, F, Jovic, S, Rodriguez, BF, Gupta, SV, Jin, F, Piumatti, G, Lo Presti, G, Pellanda, AF, Biggiogero, M, Tarkowski, M, Pizzuto, MS, Cameroni, E, Havenar-Daughton, C, Smithey, M, Hong, D, Lepori, V, Albanese, E, Ceschi, A, Bernasconi, E, Elzi, L, Ferrari, P, Garzoni, C, Riva, A, Snell, G, Sallusto, F, Fink, K, Virgin, HW, Lanzavecchia, A, Corti, D, Veesler, D, Piccoli, L, Park, YJ, Tortorici, MA, Czudnochowski, N, Walls, AC, Beltramello, M, Silacci-Fregni, C, Pinto, D, Rosen, LE, Bowen, JE, Acton, OJ, Jaconi, S, Guarino, B, Minola, A, Zatta, F, Sprugasci, N, Bassi, J, Peter, A, De Marco, A, Nix, JC, Mele, F, Jovic, S, Rodriguez, BF, Gupta, SV, Jin, F, Piumatti, G, Lo Presti, G, Pellanda, AF, Biggiogero, M, Tarkowski, M, Pizzuto, MS, Cameroni, E, Havenar-Daughton, C, Smithey, M, Hong, D, Lepori, V, Albanese, E, Ceschi, A, Bernasconi, E, Elzi, L, Ferrari, P, Garzoni, C, Riva, A, Snell, G, Sallusto, F, Fink, K, Virgin, HW, Lanzavecchia, A, Corti, D, and Veesler, D
- Abstract
Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune protection and identifying targets for vaccine design. In a cohort of 647 SARS-CoV-2-infected subjects, we found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores. The receptor-binding domain (RBD) is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 immune sera. Whereas overall RBD-specific serum IgG titers waned with a half-life of 49 days, nAb titers and avidity increased over time for some individuals, consistent with affinity maturation. We structurally defined an RBD antigenic map and serologically quantified serum Abs specific for distinct RBD epitopes leading to the identification of two major receptor-binding motif antigenic sites. Our results explain the immunodominance of the receptor-binding motif and will guide the design of COVID-19 vaccines and therapeutics.
- Published
- 2020
22. Predicting the pathogen of diabetic toe osteomyelitis by two consecutive ulcer cultures with bone contact
- Author
-
Bernard, L., Assal, M., Garzoni, C., and Uçkay, I.
- Published
- 2011
- Full Text
- View/download PDF
23. Incidence and Clinical Significance of CMV Disease in a Countrywide Prospective Cohort of Solid-Organ Transplant Recipients.: Abstract# 1497 Poster Board #-Session: P59-IV
- Author
-
Manuel, O., Kralidis, G., Mueller, N. J., Garzoni, C., Hirsch, H. H., Weisser, M., Van Delden, C., Berger, C., Boggian, K., Pascual, M., and Meylan, P.
- Published
- 2012
24. New azoles as first line therapy for Paecilomyces lilacinus in transplant patients
- Author
-
Garzoni, C. and Garbino, J.
- Published
- 2008
25. PTX3 Polymorphisms and Invasive Mold Infections After Solid Organ Transplant
- Author
-
Wójtowicz, A., Lecompte, T.D., Bibert, S., Manuel, O., Rüeger, S., Berger, C., Boggian, K., Cusini, A., Garzoni, C., Hirsch, H., Khanna, N., Mueller, N.J., Meylan, P.R., Pascual, M., van Delden, C., Bochud, P.Y., University of Zurich, Bochud, Pierre-Yves, Swiss Transplant Cohort Study, Achermann, R., Aubert, JD., Baumann, P., Beldi, G., Benden, C., Berger, C., Binet, I., Bochud, PY., Boely, E., Bucher, H., Bühler, L., Carell, T., Catana, E., Chalandon, Y., de Geest, S., de Rougemont, O., Dickenmann, M., Duchosal, M., Fehr, T., Ferrari-Lacraz, S., Garzoni, C., Gasche, Y., Soccal, PG., Giostra, E., Golshayan, D., Good, D., Hadaya, K., Hess, C., Hillinger, S., Hirsch, HH., Hofbauer, G., Huynh-Do, U., Immer, F., Klaghofer, R., Koller, M., Kuntzen, T., Laesser, B., Lehmann, R., Lovis, C., Manuel, O., Marti, HP., Martin, PY., Meylan, P., Mohacsi, P., Morard, I., Morel, P., Mueller, U., Mueller, NJ., Mueller-McKenna, H., Müller, T., Müllhaupt, B., Nadal, D., Nair, G., Pascual, M., Passweg, J., Ziegler, CP., Rick, J., Roosnek, E., Rosselet, A., Rothlin, S., Ruschitzka, F., Schanz, U., Schaub, S., Seiler, C., Semmo, N., Stampf, S., Steiger, J., Toso, C., Tsinalis, D., Van Delden, C., Venetz, JP., Villard, J., Wick, M., Wilhelm, M., and Yerly, P.
- Subjects
10234 Clinic for Infectious Diseases ,ddc:616 ,10219 Clinic for Gastroenterology and Hepatology ,10036 Medical Clinic ,10209 Clinic for Cardiology ,C-Reactive Protein/genetics ,Female ,Fungi/isolation & purification ,Humans ,Immunocompromised Host ,Male ,Mycoses/genetics ,Mycoses/immunology ,Organ Transplantation/adverse effects ,Polymorphism, Genetic ,Prospective Studies ,Serum Amyloid P-Component/genetics ,610 Medicine & health ,2725 Infectious Diseases ,2726 Microbiology (medical) - Abstract
Donor PTX3 polymorphisms were shown to influence the risk of invasive aspergillosis among hematopoietic stem cell transplant recipients. Here, we show that PTX3 polymorphisms are independent risk factors for invasive mold infections among 1101 solid organ transplant recipients, thereby strengthening their role in mold infection pathogenesis and patients' risk stratification.
- Published
- 2015
- Full Text
- View/download PDF
26. Rare mycotic infections in tsunami survivors: O2.2
- Author
-
Garzoni, C., Djordjevic, M., Ugkay, I., Bouchuigui-Waf, K., Legout, L., Rilliet, B., Bernard, L., and Garbino, J.
- Published
- 2005
27. Whole genome expression profiling of intracellular Staphylococcus aureus in human lung epithelial cells: P1762
- Author
-
Garzoni, C., Francois, P., Couzinet, S., Tapparel, C., Renzoni, A., Lew, D., Vaudaux, P., Kelley, W., and Schrenzel, J.
- Published
- 2005
28. Multiple splenic abscesses due to Bartonella henselae
- Author
-
Garzoni, C., Jacomella, V., Gayer, R., and Mombelli, G.
- Published
- 2003
29. Swiss Transplant Cohort Study (STCS). Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections
- Author
-
Héquet D, Kralidis G, Carrel T, Cuisini A, Garzoni C, and Hullin R
- Published
- 2016
30. Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study
- Author
-
Neofytos, D, Chatzis, O, Nasioudis, D, Boely Janke, E, Doco Lecompte, T, Garzoni, C, Berger, C, Cussini, A, Boggian, K, Khanna, N, Manuel, O, Mueller, N J, van Delden, C, Swiss Transplant Cohort Study, University of Zurich, and Neofytos, D
- Subjects
10234 Clinic for Infectious Diseases ,Transplantation ,10219 Clinic for Gastroenterology and Hepatology ,Infectious Diseases ,10036 Medical Clinic ,2747 Transplantation ,10209 Clinic for Cardiology ,610 Medicine & health ,2725 Infectious Diseases ,10178 Clinic for Pneumology - Published
- 2018
31. Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study
- Author
-
Neofytos, Dionysios, Chatzis, Olga, Nasioudis, Dimitrios, Boely Janke, E, Doco Lecompte, Thanh, Garzoni, C, Berger, C, Cussini, A, Boggian, K, Khanna, N, Manuel, O, Mueller, N J, Chalandon, Yves, Lovis, Christian, Toso, Christian, Van Delden, Christian, Villard, Jean, Swiss Transplant Cohort Study, Gasche-Soccal, Paola Marina Alessandra, and Posfay Barbe, Klara
- Subjects
Graft Rejection ,0301 basic medicine ,Male ,030230 surgery ,Aspergillosis ,Biomarkers/analysis ,chemistry.chemical_compound ,0302 clinical medicine ,Switzerland/epidemiology ,Risk Factors ,Aspergillus/isolation & purification ,Epidemiology ,Medicine ,Prospective Studies ,610 Medicine & health ,Immunosuppression/adverse effects ,Lung ,Invasive Pulmonary Aspergillosis ,ddc:616 ,ddc:618 ,ddc:617 ,Incidence (epidemiology) ,Incidence ,Invasive Pulmonary Aspergillosis/diagnosis/epidemiology/microbiology ,Middle Aged ,Lung/diagnostic imaging/microbiology ,Aspergillus ,Infectious Diseases ,Cohort ,Female ,Switzerland ,Cohort study ,Adult ,medicine.medical_specialty ,Adolescent ,030106 microbiology ,ddc:616.0757 ,03 medical and health sciences ,Galactomannan ,Young Adult ,Internal medicine ,Humans ,Aged ,Immunosuppression Therapy ,Transplantation ,Graft Rejection/prevention & control ,Organ Transplantation/adverse effects ,business.industry ,Organ Transplantation ,medicine.disease ,Transplant Recipients ,Radiography ,chemistry ,Case-Control Studies ,business ,Complication ,Biomarkers ,Follow-Up Studies - Abstract
BACKGROUND There is lack of recent multicenter epidemiological data on invasive aspergillosis (IA) among solid organ transplant recipient (SOTr) in the mold-acting antifungal era. We describe the epidemiology and outcomes of IA in a contemporary cohort of SOTr using the Swiss Transplant Cohort Study. METHODS All consecutive SOTr with proven or probable IA between 01.05.2008 and 31.12.2014 were included. A case-control study to identify IA predictors was performed: 1-case was matched with 3-controls based on SOT type, transplant center, and time post-SOT. RESULTS Among 2868 SOTr, 70 (2.4%) patients were diagnosed with proven (N: 30/70, 42.9%) or probable (N: 40/70, 57.1%) IA. The incidence of IA was 8.3%, 7.1%, 2.6%, 1.3%, and 1.2% in lung, heart, combined, kidney, and liver transplant recipients, respectively, Galactomannan immunoassay was positive in 1/3 of patients tested. Only 33/63 (52.4%) of patients presented with typical pulmonary radiographic findings. Predictors of IA included: renal insufficiency, re-operation, and bacterial and viral infections. 12-week mortality was higher in liver (85.7%, 6/7) compared to other (15.9%, 10/63; P
- Published
- 2018
32. Candida parapsilosis endocarditis: a comparative review of the literature
- Author
-
Garzoni, C., Nobre, V., Garbino, J., Garzoni, C., Nobre, V., and Garbino, J.
- Abstract
Fungal endocarditis (FE) is an uncommon disease, and while accounting for only 1.3-6% of all cases of infectious endocarditis, it carries a high mortality risk. Although Candida albicans represents the main etiology of FE, C. parapsilosis is the most common non-albicans species. We report the case of a 32-year-old man with a history of prior intravenous drug (IVD) use hospitalized with endocarditis due to C. parapsilosis and review all 71 additional cases documented in the literature. A retrospective analysis of the 72 C. parapsilosis cases compared to 52 recently reviewed cases of C. albicans endocarditis was conducted to identify organism-specific clinical peculiarities. The most common predisposing factor for C. parapsilosis endocarditis (41/72; 57.4%) involved prosthetic valves followed by IVD use (12/72; 20%). Peripheral embolic and/or hemorrhagic events occurred in 28/64 (43.8%) patients, mostly in cerebral and lower limb territories. Overall mortality was 41.7%. Combined surgical and clinical treatment was associated with a lower mortality. Few patients received the newer antifungal agents, and it would appear that more experience is required for their use in the treatment of C. parapsilosis endocarditis
- Published
- 2018
33. Predicting the pathogen of diabetic toe osteomyelitis by two consecutive ulcer cultures with bone contact
- Author
-
Bernard, L., Assal, M., Garzoni, C., Uçkay, I., Bernard, L., Assal, M., Garzoni, C., and Uçkay, I.
- Abstract
In this study, we investigate the accuracy of two consecutive ulcer cultures with bone contact compared to bone biopsy for the diagnosis of diabetic toe osteomyelitis. The same nurse and orthopaedic surgeon obtained all samples: sample A-1: bone contact swabbing through the ulcer; sample A-2: a second culture swabbing from the bone surface within 24 h; sample B: surgical bone biopsy in the operating theatre. The kappa statistic measure between samples A-1 and A-2 (bone contact swabs) indicated 82.35% agreement. The sensitivity, specificity, positive and negative predictive values of the two samples A compared to B were 96%, 79%, 92% and 88%, respectively, for the causative pathogen. These results were similar with prior antibiotic treatment, discordant bone surface swabs or with monomicrobial infections. As a conclusion, two consecutive diabetic toe cultures with bone contact accurately predict the pathogen of diabetic toe osteomyelitis in 90% of cases
- Published
- 2018
34. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients
- Author
-
Cusini, A, Béguelin, C, Stampf, S, Boggian, K, Garzoni, C, Koller, M, Manuel, O, Meylan, P, Mueller, NJ, Hirsch, HH, Weisser, M, Berger, C, van Delden, C, Achermann, R, Amico, P, Aubert, JD, Banz, V, Beldi, G, Benden, C, Binet, I, Bochud, PY, Bucher, H, Bühler, L, Carell, T, Catana, E, Chalandon, Y, de Geest, S, de Rougemont, O, Dickenmann, M, Duchosal, M, Elkrief, L, Fehr, T, Ferrari-Lacraz, S, Gasche Soccal, P, Gaudet, C, Giostra, E, Golshayan, D, Hadaya, K, Halter, J, Heim, D, Hess, C, Hillinger, S, Hofbauer, G, Huynh-Do, U, Immer, F, Klaghofer, R, Laesser, B, Lehmann, R, Lovis, C, Marti, HP, Martin, PY, Mohacsi, P, Morel, P, Mueller, U, Mueller-McKenna, H, Müller, A, Müller, T, Müllhaupt, B, Nadal, D, Pascual, M, Passweg, J, Rick, J, Roosnek, E, Rosselet, A, Rothlin, S, Ruschitzka, F, Schanz, U, Schaub, S, Schnyder, A, Seiler, C, Steiger, J, Stirnimann, G, Toso, C, Venetz, JP, Villard, J, Wick, M, Wilhelm, M, Yerly, P, Gasche-Soccal, Paola Marina Alessandra, University of Zurich, and van Delden, C
- Subjects
Graft Rejection ,Male ,genetic structures ,2747 Transplantation ,10265 Clinic for Endocrinology and Diabetology ,030230 surgery ,10234 Clinic for Infectious Diseases ,0302 clinical medicine ,Postoperative Complications ,Risk Factors ,Medicine ,2736 Pharmacology (medical) ,Immunology and Allergy ,Pharmacology (medical) ,030212 general & internal medicine ,Prospective Studies ,610 Medicine & health ,Prospective cohort study ,ddc:616 ,Incidence ,Hazard ratio ,Graft Survival ,Clostridium difficile ,Middle Aged ,Prognosis ,Anti-Bacterial Agents ,Diarrhea ,10209 Clinic for Cardiology ,2723 Immunology and Allergy ,Female ,medicine.symptom ,10178 Clinic for Pneumology ,Switzerland ,Cohort study ,medicine.medical_specialty ,03 medical and health sciences ,Internal medicine ,Humans ,Transplantation ,business.industry ,Clostridioides difficile ,Case-control study ,Organ Transplantation ,Confidence interval ,Transplant Recipients ,10036 Medical Clinic ,Case-Control Studies ,Clostridium Infections ,business ,Follow-Up Studies - Abstract
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons Clostridium difficile infection (CDI) is a leading cause of infectious diarrhea in solid organ transplant recipients (SOT). We aimed to assess incidence, risk factors, and outcome of CDI within the Swiss Transplant Cohort Study (STCS). We performed a case-control study of SOT recipients in the STCS diagnosed with CDI between May 2008 and August 2013. We matched 2 control subjects per case by age at transplantation, sex, and transplanted organ. A multivariable analysis was performed using conditional logistic regression to identify risk factors and evaluate outcome of CDI. Two thousand one hundred fifty-eight SOT recipients, comprising 87 cases of CDI and 174 matched controls were included. The overall CDI rate per 10 000 patient days was 0.47 (95% confidence interval ([CI] 0.38-0.58), with the highest rate in lung (1.48, 95% CI 0.93-2.24). In multivariable analysis, proven infections (hazard ratio [HR] 2.82, 95% CI 1.29-6.19) and antibiotic treatments (HR 4.51, 95% CI 2.03-10.0) during the preceding 3 months were independently associated with the development of CDI. Despite mild clinical presentations, recipients acquiring CDI posttransplantation had an increased risk of graft loss (HR 2.24, 95% CI 1.15-4.37; P =.02). These findings may help to improve the management of SOT recipients. ispartof: American Journal of Transplantation vol:18 issue:7 pages:1745-1754 ispartof: location:United States status: published
- Published
- 2017
35. Human microRNA responses predict cytomegalovirus replication following solid organ transplantation
- Author
-
Han, Sang Hoon, Kumar, D, Ferreira, V H, Egli, A, Hirsch, H H, Weisser, M, Garzoni, C, van Delden, C, Bochud, P Y, Manuel, O, Meylan, P, Boggian, K, Husain, S, Mueller, N J, Humar, A, Swiss Transplant Cohort Study, University of Zurich, and Kumar, D
- Subjects
10234 Clinic for Infectious Diseases ,2723 Immunology and Allergy ,610 Medicine & health ,2725 Infectious Diseases - Published
- 2017
36. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
- Author
-
Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., Zehnder, C., Boggian, K., Neofytos, D., Riat, A., Bachmann, D., Sanglard, D., Lamoth, F., and The Fungal Infection Network of Switzerland (FUNGINOS)
- Subjects
ANTIFUNGAL agents ,CANDIDA ,CANDIDA albicans ,CANDIDIASIS ,DRUG resistance in microorganisms ,GENETIC mutation ,SYMPTOMS - Abstract
Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15–77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study
- Author
-
Agüero, F., Rimola, A., Stock, P., Grossi, P., Rockstroh, J.K., Agarwal, K., Garzoni, C., Barcan, L.A., Maltez, F., Manzardo, C., Mari, M., Ragni, M.V., Anadol, E., Di Benedetto, F., Nishida, S., Gastaca, M., and Miró, J.M.
- Published
- 2016
- Full Text
- View/download PDF
38. Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study
- Author
-
Aga¼ero, F., Rimola, A., Stock, P., Grossi, P., Rockstroh, J. K., Agarwal, K., Garzoni, C., Barcan, L. A., Maltez, F., Manzardo, C., Mari, M., Ragni, M. V., Anadol, E., Di Benedetto, F., Nishida, S., Gastaca, M., Mira, J. M., Pedreira, J. D., Castro, M. A., Lapez, S., Sua¡rez, F., Vazquez, P., Blanch, J., Brunet, M., Cervera, C., de Lazzari, E., Fondevila, C., Forner, A., Fuster, J., Freixa, N., GarcAa-Valdecasas, J. C., Gil, A., Gatell, J. M., Laguno, M., Martanez, M., Mallolas, J., Monras, M., Moreno, A., Murillas, J., Paredes, D., Pacopyrightrez, I., Torres, F., Tural, C., Tuset, M., Antela, A., Fernandez, J., Losada, E., Varo, E., Lozano, R., Araiz, J. J., Barrao, E., Letona, S., Luque, P., Navarro, A., Sanjoaquan, I., Serrano, T., Tejero, E., Salcedo, M., BaA+/-ares, R., Calleja, J., Berenguer, J., Cosan, J., Gutiacopyrightrrez, I., Lapez, J. C., Miralles, P., Ramarez, M., Rincan, D., Sanchez, M., Jimacopyrightnez, M., de la Cruz, J., Ferna¡ndez, J. L., Lozano, J. M., Santoyo, J., Rodrigo, J. M., Sua¡rez, M. A., Rodraguez, M., Alonso, M. P., Asensi, V., Gonza¡lez, M. L., GonzA¡lez-Pinto, I., Rafecas, A., Carratala¡, J., Fabregat, J., Ferna¡ndez, N., Xiol, X., Montejo, M., Bustamante, J., Ferna¡ndez, J. R., Montejo, E., Ortiz de Urbina, J., Ruiz, P., Sua¡rez, M. J., Testillano, M., Valdivieso, A., Ventoso, A., Abradelo, M., Costa, J. R., Fundora, Y., Jimacopyrightnez, S., Meneu, J. C., Moreno, E., Moreno, V., Olivares, S. P., Pacopyrightrez, B., Pulido, F., Rubio, R., Blanes, M., Aguilera, V., Berenguer, M., Lapez, J., Lapez, R., Prieto, M., FariA+/-as, M. C., Arnaiz, A., Casafont, F., Echevarria, S., Fa¡brega, E., Garcaa, J. D., Gamez, M., Gutiacopyrightrrez, J. M., Peralta, F. G., Teira, R., Moreno, S., Barcena, R., Del Campo, S., Fortaºn, J., Moreno, A. M., Torre-Cisneros, J., Barrera, P., Camacho, A., Cantisa¡n, S., Castan, J. J., de la Mata, M., Lara, M. R., Natera, C., Rivero, A., Vidal, E., Castells, L. I., Charco, R., Esteban, J. I., Gavalda¡, J., Len, O., Pahissa, A., Ribera, E., Vargas, V., Pons, J. A., Cordero, E., Bernal, C., Cisneros, J. M., Gamez, M. A., Pascasio, J. M., Rodraguez, M. J., Sayazo, M., Sousa, J. M., Sua¡rez, G., Gonza¡lez, J., Aznar, E., Barquilla, E., Esteban, H., Krahe, L., Moyano, B., de la Rosa, G., Mahillo, B., Roland, M., Ascher, N., Roberts, J., Freise, C., Terrault, N., Carlson, L., Beatty, G., Chin-Hong, P., Dove, L., Emond, J., Lobritto, S., Neu, N., Yin, M., Kumar, A., Ringe, B., Jacobson, J., Sass, D., Diego, J., Tzakis, A., Roth, D., Schiff, E., Burke, G., Jayaweera, D., Olthoff, K., Blumberg, E., Bloom, R., Reddy, R., Ragni, M., Shapiro, R., De Vera, M. E., Shakil, O., Simon, D., Cohen, S. M., Dodson, S. F., Jensik, S., Saltzberg, S., Stosor, T., Green, R., Baker, T., Gallon, L., Scarsi, K., Hanto, D., Wong, M., Curry, M., Johnson, S., Pavlakis, M., Barin, B., Risaliti, A., Ancarani, F., Pinna, A. D., Morelli, C., Guaraldi, G., Tarantino, G., Baccarani, U., Tavio, M., Nanni Costa, A., Beckebaum, S., Radecke, K., Bickel, M., Sterneck, M., Zoufaly, A., Ganten, T., Stoll, M., Salzberger, B., Berg, C., Kittner, J., O'Grady, J., Joshi, D., Heaton, N., Smud, A., Genoud, N., Cahn, F., Valledor, A., Gadano, A., Barcan, L., Cusini, A., Rauch, A., Furrer, H., Ma¼ller, N. J., Khanna, N., van Delden, C., Oriol, M., Manata, M. J., Correia, F., Machado, J., Morbey, A., Glaria, H., Veloso, J., Perdigoto, R., Pereira, P., Martins, A., and Barroso, E.
- Subjects
Male ,medicine.medical_treatment ,HCC INF ,HIV Infections ,Hepacivirus ,030230 surgery ,Liver transplantation ,medicine.disease_cause ,Gastroenterology ,Cohort Studies ,0302 clinical medicine ,Postoperative Complications ,Risk Factors ,Adult ,Coinfection ,Female ,Follow-Up Studies ,Graft Survival ,HIV-1 ,Hepatitis B ,Hepatitis B virus ,Hepatitis C ,Humans ,International Agencies ,Middle Aged ,Prognosis ,Reoperation ,Survival Rate ,Liver Transplantation ,Immunology and Allergy ,Transplantation ,Pharmacology (medical) ,virus diseases ,3. Good health ,030211 gastroenterology & hepatology ,medicine.medical_specialty ,Hepatitis C virus ,03 medical and health sciences ,Internal medicine ,medicine ,Survival rate ,business.industry ,medicine.disease ,digestive system diseases ,Surgery ,business - Abstract
Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents. info:eu-repo/semantics/publishedVersion
- Published
- 2016
39. IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation
- Author
-
Wojtowicz, A., Gresnigt, M.S., Lecompte, T., Bibert, S., Manuel, O., Joosten, L.A.B., Rueger, S., Berger, C., Boggian, K., Cusini, A., Garzoni, C., Hirsch, H.H., Weisser, M., Mueller, N.J., Meylan, P.R., Steiger, J., Kutalik, Z., Pascual, M., Delden, C. van, Veerdonk, F.L. van de, Bochud, P.Y., Wojtowicz, A., Gresnigt, M.S., Lecompte, T., Bibert, S., Manuel, O., Joosten, L.A.B., Rueger, S., Berger, C., Boggian, K., Cusini, A., Garzoni, C., Hirsch, H.H., Weisser, M., Mueller, N.J., Meylan, P.R., Steiger, J., Kutalik, Z., Pascual, M., Delden, C. van, Veerdonk, F.L. van de, and Bochud, P.Y.
- Abstract
Contains fulltext : 153038.pdf (publisher's version ) (Closed access), BACKGROUND: Single-nucleotide polymorphisms (SNPs) in immune genes have been associated with susceptibility to invasive mold infection (IMI) among hematopoietic stem cell but not solid-organ transplant (SOT) recipients. METHODS: Twenty-four SNPs from systematically selected genes were genotyped among 1101 SOT recipients (715 kidney transplant recipients, 190 liver transplant recipients, 102 lung transplant recipients, 79 heart transplant recipients, and 15 recipients of other transplants) from the Swiss Transplant Cohort Study. Association between SNPs and the end point were assessed by log-rank test and Cox regression models. Cytokine production upon Aspergillus stimulation was measured by enzyme-linked immunosorbent assay in peripheral blood mononuclear cells (PBMCs) from healthy volunteers and correlated with relevant genotypes. RESULTS: Mold colonization (n = 45) and proven/probable IMI (n = 26) were associated with polymorphisms in the genes encoding interleukin 1beta (IL1B; rs16944; recessive mode, P = .001 for colonization and P = .00005 for IMI, by the log-rank test), interleukin 1 receptor antagonist (IL1RN; rs419598; P = .01 and P = .02, respectively), and beta-defensin 1 (DEFB1; rs1800972; P = .001 and P = .0002, respectively). The associations with IL1B and DEFB1 remained significant in a multivariate regression model (P = .002 for IL1B rs16944; P = .01 for DEFB1 rs1800972). The presence of 2 copies of the rare allele of rs16944 or rs419598 was associated with reduced Aspergillus-induced interleukin 1beta and tumor necrosis factor alpha secretion by PBMCs. CONCLUSIONS: Functional polymorphisms in IL1B and DEFB1 influence susceptibility to mold infection in SOT recipients. This observation may contribute to individual risk stratification.
- Published
- 2015
40. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey
- Author
-
San-Juan, R., Manuel, O., Hirsch, H. H., Fernandez-Ruiz, M., Lopez-Medrano, F., Comoli, P., Caillard, S., Grossi, P., Aguado, J. M., Alamo-Martinez, J. M., Anaya, F., Anttila, V. -J., Arnol, M., Avolio, Alfonso Wolfango, Baccarani, U., Castello, I. B., Boletis, I., Bonofiglio, R., Bressollette, C., Brockmann, J., Pulido, J. C., Catalan, P., Christiansen, C., Cofan, F., Cordero, E., Leiro, M. C., Dantal, J., D'Armini, A., Delgado, J. F., Strologo, L. D., Raimondo, F. D., Dierickx, D., Eis-Hubinger, A., Kremer, S. F., Faggian, G., Farinas, M. C., Folgueira, M. D., Fontana, I., Franco, A., Furian, L., Garzoni, C., Ghirardo, G., Ginevri, F., Grinyo, J., Gupte, G., Hansson, L., Helantera, I., Herrero, J. I., Hobin, D., Hoffmann, D., Jan, L., Jarque, I., Jespersen, B., Kaczmarek, I., Kevin, P., Koneth, I., Kovac, D., Lacaille, F., Lautenschlager, I., Len, O., Llado, L., Loy, M., Marcos Maeso, M. A., Marianne, L. V., Marsh, J., Meylan, P., Minambres, E., Montejo, M., Mueller, N., Munoz, P., Nadalin, S., Kamar, N., Nicolas, B., Olivier, D., Palomo, J., Pascual, M., Peter, J., Pierre, F., Francisca Portero, M., Provot, F., Boluda, E. R., Regalia, E., Reina, G., Reuter, S., Ricart, J., Garcia, M. R., Rollag, H., Russo, F. P., Sabe, N., Salcedo, M., Santambrogio, L., Seeman, T., Serra, N., Sgarabotto, D., Simonek, J., Thierry, Y., Thomsen, M. K., Tihic, N., Torre-Cisneros, J., Travi, G., Tulissi, P., Moal, V., Veroux, M., Santandreu, A. V., Vizzini, G., Zibar, L., Avolio A. W. (ORCID:0000-0003-2491-7625), San-Juan, R., Manuel, O., Hirsch, H. H., Fernandez-Ruiz, M., Lopez-Medrano, F., Comoli, P., Caillard, S., Grossi, P., Aguado, J. M., Alamo-Martinez, J. M., Anaya, F., Anttila, V. -J., Arnol, M., Avolio, Alfonso Wolfango, Baccarani, U., Castello, I. B., Boletis, I., Bonofiglio, R., Bressollette, C., Brockmann, J., Pulido, J. C., Catalan, P., Christiansen, C., Cofan, F., Cordero, E., Leiro, M. C., Dantal, J., D'Armini, A., Delgado, J. F., Strologo, L. D., Raimondo, F. D., Dierickx, D., Eis-Hubinger, A., Kremer, S. F., Faggian, G., Farinas, M. C., Folgueira, M. D., Fontana, I., Franco, A., Furian, L., Garzoni, C., Ghirardo, G., Ginevri, F., Grinyo, J., Gupte, G., Hansson, L., Helantera, I., Herrero, J. I., Hobin, D., Hoffmann, D., Jan, L., Jarque, I., Jespersen, B., Kaczmarek, I., Kevin, P., Koneth, I., Kovac, D., Lacaille, F., Lautenschlager, I., Len, O., Llado, L., Loy, M., Marcos Maeso, M. A., Marianne, L. V., Marsh, J., Meylan, P., Minambres, E., Montejo, M., Mueller, N., Munoz, P., Nadalin, S., Kamar, N., Nicolas, B., Olivier, D., Palomo, J., Pascual, M., Peter, J., Pierre, F., Francisca Portero, M., Provot, F., Boluda, E. R., Regalia, E., Reina, G., Reuter, S., Ricart, J., Garcia, M. R., Rollag, H., Russo, F. P., Sabe, N., Salcedo, M., Santambrogio, L., Seeman, T., Serra, N., Sgarabotto, D., Simonek, J., Thierry, Y., Thomsen, M. K., Tihic, N., Torre-Cisneros, J., Travi, G., Tulissi, P., Moal, V., Veroux, M., Santandreu, A. V., Vizzini, G., Zibar, L., and Avolio A. W. (ORCID:0000-0003-2491-7625)
- Abstract
There is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients.
- Published
- 2015
41. Efficacy of HyperDRYmist® technology in reducing residual environmental MDR bacterial contamination in tertiary hospital
- Author
-
Ferrari, M, primary, Bocconi, A, additional, Anesi, A, additional, Asticcioli, S, additional, Baroni, D, additional, and Garzoni, C, additional
- Published
- 2015
- Full Text
- View/download PDF
42. Current preventive strategies and management of Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey
- Author
-
San Juan, R, Manuel, O, Hirsch, Hh, Fernández Ruiz, M, López Medrano, F, Comoli, P, Caillard, S, Grossi, P, Aguado, Jm, Álamo Martínez JM, Anaya, F, Anttila, Vj, Arnol, M, Avolio, Aw, Baccarani, U, Castello, Ib, Boletis, I, Bonofiglio, R, Viamigliori, A, Bressollette, C, Brockmann, J, Pulido, Jc, Catalán, P, Christiansen, C, Cofan, F, Cordero, E, Leiro, Mc, Dantal, J, D'Armini, A, Delgado, Jf, Dello Strologo, L, Gesu, B, DI RAIMONDO, Francesco, Dierickx, D, Eis Hübinger, A, Kremer, Sf, Faggian, G, Fariñas, Mc, Folgueira, Md, Fontana, I, Franco, A, Furian, L, Garzoni, C, Ghirardo, G, Ginevri, F, Grinyó, J, Grossi, Pa, Gupte, G, Hansson, L, Helanterä, I, Herrero, Ji, Hobin, D, Hoffmann, D, Jan, L, Jarque, I, Jespersen, B, Kaczmarek, I, Klin, G, Kevin, P, Koneth, I, Kovac, D, Lacaille, F, Lautenschlager, I, Len, O, Lladó, L, Loy, M, Maeso, Ma, Marianne, Lv, Marsh, J, Meylan, P, Miñambres, E, Montejo, M, Mueller, N, Muñoz, P, Nadalin, S, Kamar, N, Nicolas, B, Olivier, D, Palomo, J, Pascual, M, Peter, J, Pierre, F, Portero, Mf, Provot, F, Boluda, Er, Regalia, E, Reina, G, Reuter, S, Ricart, Mj, García, Mr, Rollag, H, Russo, Fp, Sabé, N, Salcedo, M, Santambrogio, L, Seeman, T, Serra, N, Sgarabotto, D, Simonek, J, Thierry, Y, Thomsen, Mk, Tihic, N, Torre Cisneros, J, Travi, G, Tulissi, P, Moal, V, Veroux, Massimiliano, Santandreu, Av, Vizzini, G, Zibar, L., Clinicum, Department of Medicine, Infektiosairauksien yksikkö, Department of Virology, and Medicum
- Subjects
Epstein-Barr Virus Infections ,Cross-sectional study ,Settore MED/18 - CHIRURGIA GENERALE ,medicine.medical_treatment ,Medizin ,Epstein-Barr virus ,Europe ,Post-transplant lymphoproliferative disease ,Pre-emptive treatment ,Survey ,Microbiology (medical) ,Infectious Diseases ,medicine.disease_cause ,Organ transplantation ,Epstein–Barr virus ,Surveys and Questionnaires ,hemic and lymphatic diseases ,Medicine ,Tomography ,TOR Serine-Threonine Kinases ,Immunosuppression ,General Medicine ,Viral Load ,pre-emptive treatment ,X-Ray Computed ,3. Good health ,Cross-Sectional Studies ,Humans ,Immunosuppressive Agents ,Lymphoproliferative Disorders ,Positron-Emission Tomography ,Rituximab ,Tomography, X-Ray Computed ,Viremia ,Organ Transplantation ,Transplant Recipients ,post-transplant lymphoproliferative disease ,Viral load ,medicine.drug ,medicine.medical_specialty ,survey ,Internal medicine ,business.industry ,Immunology ,3111 Biomedicine ,business ,Solid organ transplantation ,Serostatus - Abstract
There is limited clinical evidence on the utility of the monitoring of Epstein–Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients.
- Published
- 2015
- Full Text
- View/download PDF
43. Pre-Transplant T-Cell Subtype Assessment as a Predictive Tool for CMV Viremia After Transplant.
- Author
-
Keshwani, S., primary, Kumar, D., additional, Lisboa, L., additional, Egli, A., additional, Bochud, P., additional, Hirsch, H., additional, Weisser, M., additional, Husain, S., additional, Garzoni, C., additional, van Delden, C., additional, Manuel, O., additional, Meylan, P., additional, Boggian, K., additional, Rick, J., additional, Mueller, N., additional, and Humar, A., additional
- Published
- 2014
- Full Text
- View/download PDF
44. Opportunistic Infections After Solid Organ Transplantation (SOT) Are Rare in The Swiss Transplant Cohort Study (STCS).
- Author
-
Mueller, N., primary, Saccilotto, R., additional, Meylan, P., additional, Manuel, O., additional, Garzoni, C., additional, Cusini, A., additional, Hirsch, H., additional, Weisser, M., additional, Khanna, N., additional, Boggian, K., additional, Nadal, D., additional, Berger, C., additional, Koller, M., additional, Stampf, S., additional, and van Delden, C., additional
- Published
- 2014
- Full Text
- View/download PDF
45. NK Cell Immunity Pre-Transplant as a Predictor for CMV Post-Transplant.
- Author
-
Keshwani, S., primary, Humar, A., additional, Lisboa, L., additional, Egli, A., additional, Bochud, P., additional, Hirsch, H., additional, Weisser, M., additional, Husain, S., additional, Garzoni, C., additional, van Delden, C., additional, Manuel, O., additional, Meylan, P., additional, Boggian, K., additional, Stern, M., additional, Rick, J., additional, Mueller, N., additional, and Kumar, D., additional
- Published
- 2014
- Full Text
- View/download PDF
46. Clostridium difficileinfection is associated with graft loss in solid organ transplant recipients
- Author
-
Cusini, A., Béguelin, C., Stampf, S., Boggian, K., Garzoni, C., Koller, M., Manuel, O., Meylan, P., Mueller, N. J., Hirsch, H. H., Weisser, M., Berger, C., Delden, C., Achermann, Rita, Amico, Patrizia, Aubert, John‐David, Banz, Vanessa, Beldi, Guido, Benden, Christian, Binet, Isabelle, Bochud, Pierre‐Yves, Bucher, Heiner, Bühler, Leo, Carell, Thierry, Catana, Emmanuelle, Chalandon, Yves, Geest, Sabina, Rougemont, Olivier, Dickenmann, Michael, Duchosal, Michel, Elkrief, Laure, Fehr, Thomas, Ferrari‐Lacraz, Sylvie, Gasche Soccal, Paola, Gaudet, Christophe, Giostra, Emiliano, Golshayan, Déla, Hadaya, Karine, Halter, Jörg, Heim, Dominik, Hess, Christoph, Hillinger, Sven, Hofbauer, Günther, Huynh‐Do, Uyen, Immer, Franz, Klaghofer, Richard, Laesser, Bettina, Lehmann, Roger, Lovis, Christian, Marti, Hans‐Peter, Martin, Pierre Yves, Mohacsi, Paul, Morel, Philippe, Mueller, Ulrike, Mueller‐McKenna, Helen, Müller, Antonia, Müller, Thomas, Müllhaupt, Beat, Nadal, David, Pascual, Manuel, Passweg, Jakob, Rick, Juliane, Roosnek, Eddy, Rosselet, Anne, Rothlin, Silvia, Ruschitzka, Frank, Schanz, Urs, Schaub, Stefan, Schnyder, Aurelia, Seiler, Christian, Steiger, Jürg, Stirnimann, Guido, Toso, Christian, Venetz, Jean‐Pierre, Villard, Jean, Wick, Madeleine, Wilhelm, Markus, and Yerly, Patrick
- Abstract
Clostridium difficileinfection (CDI) is a leading cause of infectious diarrhea in solid organ transplant recipients (SOT). We aimed to assess incidence, risk factors, and outcome of CDIwithin the Swiss Transplant Cohort Study (STCS). We performed a case‐control study of SOTrecipients in the STCSdiagnosed with CDIbetween May 2008 and August 2013. We matched 2 control subjects per case by age at transplantation, sex, and transplanted organ. A multivariable analysis was performed using conditional logistic regression to identify risk factors and evaluate outcome of CDI. Two thousand one hundred fifty‐eight SOTrecipients, comprising 87 cases of CDIand 174 matched controls were included. The overall CDIrate per 10 000 patient days was 0.47 (95% confidence interval ([CI] 0.38‐0.58), with the highest rate in lung (1.48, 95% CI0.93‐2.24). In multivariable analysis, proven infections (hazard ratio [HR] 2.82, 95% CI1.29‐6.19) and antibiotic treatments (HR 4.51, 95% CI2.03‐10.0) during the preceding 3 months were independently associated with the development of CDI. Despite mild clinical presentations, recipients acquiring CDIposttransplantation had an increased risk of graft loss (HR2.24, 95% CI1.15‐4.37; P= .02). These findings may help to improve the management of SOTrecipients. The authors demonstrate that despite mild clinical presentations and good clinical responses, Clostridium difficileinfections are associated with an increased risk of graft loss in the Swiss Transplant Cohort Study.
- Published
- 2018
- Full Text
- View/download PDF
47. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study
- Author
-
Khanna, N, Elzi, L, Mueller, N J, Garzoni, C, Cavassini, M, Fux, C A, Vernazza, P, Bernasconi, E, Battegay, M, Hirsch, H H, Khanna, N, Elzi, L, Mueller, N J, Garzoni, C, Cavassini, M, Fux, C A, Vernazza, P, Bernasconi, E, Battegay, M, and Hirsch, H H
- Abstract
BACKGROUND: We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996. METHODS: From 1988 through 2007, 226 cases of PML were reported to the Swiss HIV Cohort Study. By chart review, we confirmed 186 cases and recorded all-cause and PML-attributable mortality. For the survival analysis, 25 patients with postmortem diagnosis and 2 without CD4+ T cell counts were excluded, leaving a total of 159 patients (89 before 1996 and 70 during 1996-2007). RESULTS: The incidence rate of PML decreased from 0.24 cases per 100 patient-years (PY; 95% confidence interval [CI], 0.20-0.29 cases per 100 PY) before 1996 to 0.06 cases per 100 PY (95% CI, 0.04-0.10 cases per 100 PY) from 1996 onward. Patients who received a diagnosis before 1996 had a higher frequency of prior acquired immunodeficiency syndrome-defining conditions (P = .007) but similar CD4+ T cell counts (60 vs. 71 cells/microL; P = .25), compared with patients who received a diagnosis during 1996 or thereafter. The median time to PML-attributable death was 71 days (interquartile range, 44-140 days), compared with 90 days (interquartile range, 54-313 days) for all-cause mortality. The PML-attributable 1-year mortality rate decreased from 82.3 cases per 100 PY (95% CI, 58.8-115.1 cases per 100 PY) during the pre-cART era to 37.6 cases per 100 PY (95% CI, 23.4.-60.5 cases per 100 PY) during the cART era. In multivariate models, cART was the only factor associated with lower PML-attributable mortality (hazard ratio, 0.18; 95% CI, 0.07-0.50; P < .001), whereas all-cause mortality was associated with baseline CD4+ T cell count (hazard ratio per increase of 100 cells/microL, 0.52; 95% CI, 0.32-0.85; P = .010) and cART use (hazard ratio, 0.37; 95% CI, 0.19-0.75; P = .006). CONCLUSIONS: cART reduced the incidence and PML-attributable 1-year mortality
- Published
- 2009
48. Colonisation with Pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients
- Author
-
Engler, K, primary, Mühlemann, K, additional, Garzoni, C, additional, Pfahler, H, additional, Geiser, T, additional, and von, Garnier, additional
- Published
- 2012
- Full Text
- View/download PDF
49. Quantitative PCR to diagnosePneumocystispneumonia in immunocompromised non-HIV patients
- Author
-
Mühlethaler, K., primary, Bögli-Stuber, K., additional, Wasmer, S., additional, von Garnier, C., additional, Dumont, P., additional, Rauch, A., additional, Mühlemann, K., additional, and Garzoni, C., additional
- Published
- 2011
- Full Text
- View/download PDF
50. Emergence of four cases of KPC-2 and KPC-3-carrying Klebsiella pneumoniae introduced to Switzerland, 2009–10
- Author
-
Babouee, B, primary, Widmer, A F, additional, Dubuis, O, additional, Ciardo, D, additional, Droz, S, additional, Betsch, B Y, additional, Garzoni, C, additional, Führer, U, additional, Battegay, M, additional, Frei, R, additional, and Goldenberger, D, additional
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.